乾眼症症候群 - 印度的藥物預測與市場分析
Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024
|出版日期||內容資訊||英文 194 Pages
|乾眼症症候群 - 印度的藥物預測與市場分析 Dry Eye Syndrome - India Drug Forecast and Market Analysis to 2024|
|出版日期: 2015年11月05日||內容資訊: 英文 194 Pages||
Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis' recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market.
Diagnosis and treatment rates are expected to increase slightly for all severities of DES in India over the course of the forecast period. This rise in treatment is mainly due to improving disease awareness among both physicians and patients, which will be the main source of growth in this otherwise stagnant market. Allergan's Restasis is the only approved prescription DES drug in the Indian dry eye market, and was the leading drug (ahead of artificial tears products) in 2014.